ライフサイエンスコーパス: preventive treatment

1 protection and potentially can be used as a preventive treatment.

2 nfection suggest an enormous opportunity for preventive treatment.

3 r active tuberculosis were offered isoniazid preventive treatment.

4 re born to mothers who received intermittent preventive treatment.

5 M-CSF showed neuroprotective effects as a preventive treatment.

6 ing the costs of disease against that of the preventive treatment.

7 ed with the highest coverage of intermittent preventive treatment.

8 ronary endothelial function as the basis for preventive treatment.

9 in guidelines and recommended for targeting preventive treatment.

10 o benefit from early spectacle correction or preventive treatment.

11 arly marker of preclinical CAD for potential preventive treatment.

12 on-induced gut injury is needed to develop a preventive treatment.

13 ased headache frequency is an indication for preventive treatment.

14 Patients with VB events require active preventive treatment.

15 culosis control by more precise targeting of preventive treatment.

16 ad hepatotoxic reactions to isoniazid during preventive treatment.

17 y-two percent of PMP women were receiving no preventive treatment.

18 re inadequate and there is limited access to preventive treatment.

19 al malaria chemoprevention, and intermittent preventive treatment.

20 erculosis (RR/MDR-TB), and many more require preventive treatment.

21 on can prevent invasive treatment and enable preventive treatment.

22 0.0-28.0), and 232 (28%) had previously used preventive treatment.

23 r disease, which is a missed opportunity for preventive treatment.

24 e sulfadoxine-pyrimethamine for intermittent preventive treatment.

25 ies the possibility of new targets for broad preventive treatments.

26 ic higher risk group potentially amenable to preventive treatments.

27 periods and may be useful for initiation of preventive treatments.

28 ven when used in addition to other secondary preventive treatments.

29 e human disease, enabling the exploration of preventive treatments.

30 by two to four classes of conventional oral preventive treatments.

31 um pre-eclampsia is limited and there are no preventive treatments.

32 on a suitable target for Alzheimer's disease preventive treatments.

33 despite anticoagulation to develop improved preventive treatments.

34 ir diagnostic studies and optimise acute and preventive treatments.

35 week that were unsuccessfully controlled by preventive treatments.

36 evelop epilepsy and which might benefit from preventive treatments.

37 psychosis and more effective and potentially preventive treatments.

38 ascular Risk Using SIGN Guidelines to Assign Preventive Treatment]).

39 sessed the efficacy of seasonal intermittent preventive treatment-a full dose of antimalarial treatme

40 The month of onset of preventive treatment action was assessed.

41 to sulfadoxine-pyrimethamine as intermittent preventive treatment against malaria in pregnancy (IPTp)

42 during intervention, and usual intermittent preventive treatment against malaria was given.

43 ights have enormous potential for developing preventive treatments against bacterial infections.

44 This would aid the design of preventive treatments against the rapid decline of CD4(+

45 ng a pathway to greatly improve vaccines and preventive treatments against these important pathogens.

46 tance dispersal, but combining curative with preventive treatments ahead of the front reduced local d

47 These new advances in preventive treatment and a better understanding of its r

48 seen in two of 24 countries for intermittent preventive treatment and in three of 30 countries for in

49 existing interventions, such as intermittent preventive treatment and use of impregnated bed nets, we

50 Although coverage of intermittent preventive treatment and use of insecticide-treated nets

51 ors associated with coverage of intermittent preventive treatment and use of insecticide-treated nets

52 0 years in association with increased use of preventive treatments and major reductions in premorbid

53 multi-disease campaign, offering diagnostic, preventive, treatment and referral services, was perform

54 ed changes in invasive coronary angiography, preventive treatments, and clinical outcomes using natio

55 diagnosis on invasive coronary angiography, preventive treatments, and clinical outcomes.

56 Early diagnosis and preventive treatment are instrumental to prevent sudden

57 childhood screening, parental education, and preventive treatments are known to reduce mortality.

58 rlying arterial pathology, risk factors, and preventive treatments, but they are rarely studied concu

59 ed on admission into the Early Diagnosis and Preventive Treatment Clinic, an outpatient clinic specia

60 Intermittent preventive treatment could be highly effective for preve

61 studies suggest that urgent use of existing preventive treatments could reduce the risk by 80-90%, b

62 rt of diagnosing osteoporosis and deciding a preventive treatment course.

63 Preventive treatment decreases migraine frequency and im

64 However, through 2 years, preventive treatment did not confer visual acuity benefi

65 emoglobin concentration, use of intermittent preventive treatment during pregnancy (IPTp) for malaria

66 e antimalarial effectiveness of intermittent preventive treatment during pregnancy (IPTp) in sub-Saha

67 Intermittent preventive treatment during pregnancy (IPTp) with sulfad

68 Intermittent preventive treatment during pregnancy (IPTp) with sulfad

69 Intermittent preventive treatment during pregnancy with SP may contin

70 domly assigned (1:1) to monthly intermittent preventive treatment during pregnancy with sulfadoxine-p

71 Preventive treatment effectively lowers the risk of dise

72 echanisms of pathogenesis are unknown and no preventive treatments exist.

73 ly Vitamin A has proven a safe and effective preventive treatment for BPD.

74 spirin is a common, chronically administered preventive treatment for cardiovascular disease, but is

75 inued development of the laser as a possible preventive treatment for caries.

76 y is warranted of tuberculosis screening and preventive treatment for children at high-risk of this d

77 Fremanezumab as a preventive treatment for chronic migraine resulted in a

78 to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.

79 ere is currently no effective therapeutic or preventive treatment for DENV infection.

80 Intermittent preventive treatment for malaria during infancy (IPTi) i

81 co-trimoxazole prophylaxis and intermittent preventive treatment for malaria in pregnant women (IPTp

82 long-lasting insecticidal nets, intermittent preventive treatment for malaria, regular anthelmintic d

83 Although evidence for estrogen as a preventive treatment for menstrual migraine is inconsist

84 d peptide (CGRP), is being investigated as a preventive treatment for migraine.

85 There is no preventive treatment for patients at risk.

86 Step I diet, statin therapy, and no preventive treatment for primary and secondary preventio

87 No preventive treatment for this disease is available.

88 ts and pulmonary biologists have long sought preventive treatments for bronchopulmonary dysplasia (BP

89 The benefits of screening and preventive treatments for individuals with cancer-relate

90 o the diagnostic end point in assessments of preventive treatments for the disorder.

91 d stroke, risk factors, and premorbid use of preventive treatments from 1981-84 (Oxford Community Str

92 to better understand etiology, mechanism and preventive treatments going forward.

93 Significant benefits for the OT preventive treatment group were found across various hea

94 the World Health Organization updated its TB preventive treatment guidelines to make a strong recomme

95 with migraine for whom two to four previous preventive treatments had failed to provide a benefit.

96 for whom multiple previous standard-of-care preventive treatments had failed.

97 Many patients who require migraine preventive treatment have not been able to tolerate or h

98 Although pharmacological preventive treatments have been shown to offer some bene

99 nical trials have documented the efficacy of preventive treatment in asymptomatic women.

100 hallenges and opportunities for tuberculosis preventive treatment in carceral settings.

101 d the efficacy and safety of levofloxacin as preventive treatment in children with household exposure

102 prevention, previously known as intermittent preventive treatment in children, is highly effective in

103 Intermittent preventive treatment in infants (IPTi) is a new malaria

104 Intermittent preventive treatment in infants (IPTi) is the administra

105 trial in Tanzania suggest that intermittent preventive treatment in infants (IPTi), delivered throug

106 thamine at times of vaccination-intermittent preventive treatment in infants (IPTi)-is a promising st

107 e fraction of recipients, while intermittent preventive treatment in infants provides modest partial

108 on that caution is needed for downscaling of preventive treatment in patients with zero CAC, chest pa

109 andomized, controlled trials on tuberculosis preventive treatment in persons exposed to MDR tuberculo

110 women in sub-Saharan Africa of intermittent preventive treatment in pregnancy (IPTp) and insecticide

111 In a recent trial of intermittent preventive treatment in pregnancy (IPTp) in Uganda, dihy

112 Intermittent preventive treatment in pregnancy (IPTp) is used to prev

113 Understanding the role of intermittent preventive treatment in pregnancy (IPTp) on the selectio

114 Intermittent preventive treatment in pregnancy (IPTp) with dihydroart

115 the efficacy of WHO-recommended intermittent preventive treatment in pregnancy (IPTp) with single-dos

116 Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxin

117 on of which primarily relies on intermittent preventive treatment in pregnancy (IPTp) with sulfadoxin

118 continues to be recommended for intermittent preventive treatment in pregnancy (IPTp).

119 Intermittent preventive treatment in pregnancy reduces infection risk

120 imate the cost-effectiveness of intermittent preventive treatment in pregnancy with dihydroartemisini

121 insecticidal nets together with intermittent preventive treatment in pregnancy with sulfadoxine-pyrim

122 alth workers (CHWs) to standard intermittent preventive treatment in pregnancy with sulfadoxine-pyrim

123 effective and well tolerated in intermittent preventive treatment in pregnant women and children.

124 ke incidence, major risk factors, and use of preventive treatments in an ageing population are requir

125 ecessitating a safety assessment of migraine preventive treatments in this patient subgroup.

126 rm or for greater occipital nerve block, and preventive treatments include verapamil, lithium, melato

127 estimates for 2007, coverage of intermittent preventive treatment increased from 13.1% (11.9-14.3) to

128 TB case finding, treatment of TB, isoniazid preventive treatment, infection control, administration

129 aimed to review the coverage of intermittent preventive treatment, insecticide-treated nets, and ante

130 heart disease (CHD) risk assessment to guide preventive treatment intensity.

131 havioral markers, risk prediction tools, and preventive/treatment interventions.

132 Intermittent preventive treatment (IPT) for malaria is used in infant

133 2017, Malawi scaled up continuous isoniazid preventive treatment (IPT) for tuberculosis prevention a

134 We examined the effect of intermittent preventive treatment (IPT) in reducing anaemia and impro

135 Intermittent preventive treatment (IPT) in schoolchildren offers a pr

136 Intermittent preventive treatment (IPT) of malaria has recently been

137 Intermittent preventive treatment (IPT) of malaria with dihydroartemi

138 ) is used throughout Africa for intermittent preventive treatment (IPT) of malaria, but resistance th

139 Intermittent preventive treatment (IPT) of school-aged children with

140 We hypothesised that monthly intermittent preventive treatment (IPT) or intermittent screening and

141 s study was to find out whether intermittent preventive treatment (IPT) with a fixed-dose combination

142 Intermittent preventive treatment (IPT) with dihydroartemisinin-piper

143 enrollment, followed by either intermittent preventive treatment (IPT) with SP at 4 and 8 weeks and

144 Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethami

145 with sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP) on malaria risk in HIV-pos

146 hree daily doses of amodiaquine intermittent preventive treatment (IPTi) or placebo.

147 Intermittent preventive treatment (IPTp) for pregnant women with sulf

148 Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women

149 ategy for sub-Saharan Africa of intermittent-preventive-treatment (IPTp) with two doses of sulphadoxi

150 ening and treatment showed that intermittent preventive treatment is a promising alternative treatmen

151 underlying mechanisms remain unknown and no preventive treatment is available.

152 Completion of tuberculosis (TB) preventive treatment is important to optimize efficacy;

153 roke, and what evidence there is that urgent preventive treatment is likely to be effective in reduci

154 However, development of preventive treatments is difficult because only a subset

155 Three general strategies emerge: global preventive treatment, local treatment within a neighborh

156 ase starts in early infancy, suggesting that preventive treatment may be most beneficial.

157 h-transmission regions (such as intermittent preventive treatment) may require further evaluation; ap

158 opment of neuroimaging surrogate markers and preventive treatments might eventually lead to so-called

159 ished, especially since early diagnostic and preventive-treatment modalities are limited.

160 partments to scale up the LTBI screening and preventive treatment needed to advance progress toward T

161 partments to scale up the LTBI screening and preventive treatment needed to advance progress towards

162 ol in cardiovascular risk stratification and preventive treatment of asymptomatic patients with uncle

163 These compounds are good candidates for the preventive treatment of cataract, age-related macular de

164 the further development of TEV-48125 for the preventive treatment of chronic migraine in a phase 3 tr

165 afety, and tolerability of atogepant for the preventive treatment of chronic migraine.

166 125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.

167 For the preventive treatment of extracorporeal cytokine adsorpti

168 was safe, well tolerated, and effective as a preventive treatment of high-frequency episodic migraine

169 125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine

170 Preventive treatment of LTBI resulted in a 1.8-fold aver

171 fadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp).

172 Preventive treatment of malaria among school-aged childr

173 Intermittent preventive treatment of malaria during pregnancy (IPTp)

174 Intermittent preventive treatment of malaria during pregnancy (IPTp)

175 changed its recommendation for intermittent preventive treatment of malaria during pregnancy (IPTp)

176 Intermittent preventive treatment of malaria in children (IPTc) is a

177 008-2009, as well as a trial of intermittent preventive treatment of malaria in infants in Navrongo,

178 However, SP is used as an intermittent preventive treatment of malaria in pregnancy (IPTp) and

179 randomized controlled trial of intermittent preventive treatment of malaria in pregnancy (IPTp) from

180 Intermittent preventive treatment of malaria in pregnancy (IPTp) with

181 the continuing low coverage of intermittent preventive treatment of malaria in pregnancy (IPTp).

182 oaches might increase uptake of intermittent preventive treatment of malaria in pregnancy with sulfad

183 randomized controlled trial of intermittent preventive treatment of malaria in pregnancy.

184 We aimed to assess whether preventive treatment of malaria might be an effective me

185 akers and programme managers should consider preventive treatment of malaria to protect this age grou

186 Galcanezumab was superior to placebo in the preventive treatment of migraine and was safe and well t

187 atment contraindicated or unsuitable for the preventive treatment of migraine for the patient.

188 the efficacy and safety of atogepant for the preventive treatment of migraine from December 14, 2018,

189 y evidence for the efficacy of ALD403 in the preventive treatment of migraine in patients with a high

190 her, we outline best practices for acute and preventive treatment of migraine in various patient popu

191 ceptor antagonist, has been approved for the preventive treatment of migraine, but its efficacy and s

192 onin gene-related peptide antibodies for the preventive treatment of migraine.

193 the efficacy of rimegepant with placebo for preventive treatment of migraine.

194 very other day, rimegepant was effective for preventive treatment of migraine.

195 r safety, tolerability, and efficacy for the preventive treatment of migraine.

196 , supporting its phase 3 development for the preventive treatment of migraine.

197 ntagonist that is being investigated for the preventive treatment of migraine.

198 ious pharmacological therapies for acute and preventive treatment of migraine.

199 proven effective and well tolerated for the preventive treatment of migraine.

200 significant efficacy for either the acute or preventive treatment of migraine.

201 indings could yield the need for intensified preventive treatment of patients with diabetes mellitus

202 We found that preventive treatment of Tg2576 mice with valsartan signi

203 aling as an attractive target for developing preventive treatments of epilepsy in humans.

204 scular risk may be used for the targeting of preventive treatments of individual patients who are asy

205 le-blind trial of the effect of intermittent preventive treatment on morbidity from malaria in three

206 Atogepant might be an effective preventive treatment option for patients in this difficu

207 A), a farnesoid-X-receptor (FXR) agonist, as preventive treatment options for neonatal hyperbilirubin

208 a spectrum disorder, a relative abundance of preventive treatment options now exists.

209 Conclusion Routine preventive treatment or periodic, indefinite imaging fol

210 orts of 1000 women who received intermittent preventive treatment or single screening and treatment.

211 ementation of a school-wide TB screening and preventive treatment program, we observed a significant

212 a programmatic perspective the conception of preventive treatment programs targeting both diseases si

213 comes associated with CTE and for developing preventive treatment programs.

214 existing international guidelines, possible preventive treatments, rationales for different manageme

215 ting to childhood stroke; however, acute and preventive treatment recommendations are based on interv

216 At 24 months, our pooled analysis showed preventive treatment reduced the risk of clinical seizur

217 A fluoroquinolone-based preventive treatment regimen for drug-resistant TB expos

218 retroviral treatment coverage, and effective preventive treatment regimens.

219 In sensitivity analyses, coverage of primary preventive treatments remained cost-effective even if ad

220 rapies relative to other available acute and preventive treatments remains to be determined, a growin

221 single screening and treatment, intermittent preventive treatment resulted in an incremental cost of

222 We propose that preventive treatment should pay more attention to molecu

223 Coverage of intermittent preventive treatment showed greater inequity overall tha

224 id in the identification of patients in whom preventive treatment strategies are effective.

225 ease progression are not known and effective preventive treatment strategies are lacking.

226 diate-term outcome measure for evaluation of preventive treatment strategies.

227 ymptomatic diagnosis and could lead to early preventive treatment strategies.

228 t global healthcare problem for which novel (preventive) treatment strategies are urgently needed.

229 In the search for a preventive treatment strategy, we tested the effect of s

230 have shown a conclusive benefit of a single preventive treatment strategy.

231 d MDD and to probe modulation of mGluR5 as a preventive/treatment strategy.

232 LTBI testing and preventive treatment (TB specific prevention) are recomm

233 ated, and urban women more likely to receive preventive treatment than their poorer, uneducated, rura

234 ne bone density testing and to have received preventive treatments than were patients of other specia

235 Preventive treatment that reduces CVD by even a small pe

236 depends on a relative cost of palliative and preventive treatment, the details of the local strategy

237 lying epileptogenesis and discover potential preventive treatments, the lack of PIE biomarkers hinder

238 value for the development and evaluation of preventive treatment therapies.

239 progression, allowing targeted provision of preventive treatment to those at highest risk of tubercu

240 e future, genetic testing may allow specific preventive treatments to be delivered to individuals at

241 Globally, the uptake of tuberculosis-preventive treatment (TPT) among children with household

242 s diagnostic gap and scaling up tuberculosis preventive treatment (TPT) are two global priorities to

243 Although prior studies of tuberculosis-preventive treatment (TPT) for pregnant people with huma

244 Adherence to tuberculosis preventive treatment (TPT) is an important determinant o

245 uidelines and implementation of tuberculosis preventive treatment (TPT) vary by age and HIV status.

246 B) may facilitate diagnosis and access to TB preventive treatment (TPT).

247 After 4 weeks of preventive treatment, tumors formed in 12.5, 50, and 100

248 culosis disease, HIV infection, tuberculosis preventive treatment usage, and for household contacts,

249 Preventive treatment use did not differ significantly.

250 infection risk were modified by intermittent preventive treatment use.

251 2009-11 to estimate coverage of intermittent preventive treatment, use of insecticide-treated nets, a

252 ed that in high-burden settings, stratifying preventive treatment using single-gene transcripts had g

253 ong pregnant women who received intermittent preventive treatment using sulfadoxine-pyrimethamine (IP

254 Preventive treatment using TCSs of various potencies, ad

255 In Liberia during the wet season, malaria preventive treatment was cost saving even when average d

256 The higher cost of intermittent preventive treatment was driven by monthly administratio

257 Effects of preventive treatment were analyzed based on serum antibo

258 PARTICIPANTS: Cascade case-finding and early preventive treatment were modeled to simulate the progre

259 No adverse events related to preventive treatment were noted.

260 of WHO's 2012 policy update for intermittent preventive treatment, which aims to simplify the message

261 Our findings suggest that effective preventive treatments will need to eliminate these small

262 Preventive treatment with an antibody that sequesters ne

263 The association between SES and secondary preventive treatment with antiplatelet and statin medica

264 this study was to determine whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD

265 droartemisinin-piperaquine, and intermittent preventive treatment with dihydroartemisinin-piperaquine

266 lity, and cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine

267 rtemisinin-piperaquine (n=515), intermittent preventive treatment with dihydroartemisinin-piperaquine

268 Intermittent preventive treatment with dihydroartemisinin-piperaquine

269 esia, comparing the efficacy of intermittent preventive treatment with dihydroartemisinin-piperaquine

270 Addition of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine

271 cremental cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine

272 ssed the efficacy and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine

273 Monthly intermittent preventive treatment with dihydroartemisinin-piperaquine

274 ent girls or women who received intermittent preventive treatment with dihydroartemisinin-piperaquine

275 with sulfadoxine-pyrimethamine, intermittent preventive treatment with dihydroartemisinin-piperaquine

276 on at delivery was lower in the intermittent preventive treatment with dihydroartemisinin-piperaquine

277 hich were least frequent in the intermittent preventive treatment with dihydroartemisinin-piperaquine

278 dihydroartemisinin-piperaquine, intermittent preventive treatment with dihydroartemisinin-piperaquine

279 Preventive treatment with L. rhamnosus GG (but not L. rh

280 Although preventive treatment with levofloxacin led to a lower in

281 Intermittent preventive treatment with monthly dihydroartemisinin-pip

282 Allergy-preventive treatment with OVA, nitrated OVA (nOVA), and

283 Taken together, these data indicate that preventive treatment with paquinimod ameliorates experim

284 th weight among women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT

285 on of which primarily relies on intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT

286 misinin-piperaquine (n=516), or intermittent preventive treatment with sulfadoxine-pyrimethamine (n=5

287 n-piperaquine group than in the intermittent preventive treatment with sulfadoxine-pyrimethamine grou

288 s not a suitable alternative to intermittent preventive treatment with sulfadoxine-pyrimethamine in t

289 The effectiveness of the intermittent preventive treatment with sulfadoxine-pyrimethamine stra

290 Compared with intermittent preventive treatment with sulfadoxine-pyrimethamine, int

291 ydroartemisinin-piperaquine, or intermittent preventive treatment with sulfadoxine-pyrimethamine.

292 Intermittent preventive treatment with sulphadoxine-pyrimethamine (IP

293 Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP

294 Delivery of intermittent preventive treatment with sulphadoxine-pyrimethamine to

295 which aims to simplify the message and align preventive treatment with the focused antenatal care sch

296 Here, we show that preventive treatment with the Q compound paquinimod (ABR

297 d prevention strategies include intermittent preventive treatment with two doses of sulfadoxine-pyrim

298 Preventive treatment with vigabatrin was safe and modifi

299 Notably, preventive treatment with VNP expressing shielded allerg

300 n, results-based financing, and intermittent-preventive-treatment with sulphadoxine-pyrimethamine (IP